A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to compare the radiographic progression-free survival (rPFS) of
apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone
(AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any
chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate
cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of
sperm]).